Single-cell RNA sequencing identifies a paracrine interaction that may drive oncogenic notch signaling in human adenoid cystic carcinoma-Reference-Cited by-同舟云学术

Single-cell RNA sequencing identifies a paracrine interaction that may drive oncogenic notch signaling in human adenoid cystic carcinoma

Published:2022-11 Issue:9 Volume:41 Page:111743
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Parikh Anuraag S.^ORCID,Wizel Avishai,Davis Daniel,Lefranc-Torres Armida,Rodarte-Rascon Alejandro I.,Miller Lauren E.,Emerick Kevin S.,Varvares Mark A.,Deschler Daniel G.,Faquin William C.,Aster Jon C.,Lin Derrick T.,Bernstein Bradley E.,Drier Yotam,Puram Sidharth V.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference51 articles.

1. Adenoid cystic carcinoma: emerging role of translocations and gene fusions;Wysocki;Oncotarget,2016

2. Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma;Brayer;Cancer Discov.,2016

3. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck;Persson;Proc. Natl. Acad. Sci. USA,2009

4. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma;Drier;Nat. Genet.,2016

5. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma;Ho;J. Clin. Invest.,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advances;MedComm;2024-09

2. Integrative analysis reveals a macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer;2024-06-13

3. Emerging role of MYB transcription factors in cancer drug resistance;Cancer Drug Resistance;2024-04-30

4. The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma;FEBS Letters;2023-12-27

5. A phase 2 study of MK‐2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104);Cancer;2023-11-10